A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohnâ¤*s Disease

Published: 09-11-2010
Last updated: 04-05-2024

Primary: to assess the efficacy of GSK1605786A compared with placebo as an induction therapy in subjects with moderately-to-severely active Crohn*s disease over 12 weeks.
Secondary: Safety, quality of life, healthcare resource utilisation, PK,...

Ethical review	Approved WMO
Status	Pending
Health condition type	Gastrointestinal inflammatory conditions
Study type	Interventional

Summary

ID

NL-OMON36819

Source
ToetsingOnline

Brief title
CCX114151

Condition

- Gastrointestinal inflammatory conditions

Synonym
Crohn's disease

Research involving

Human

Sponsors and support

Primary sponsor: GlaxoSmithKline
Source(s) of monetary or material Support: GlaxoSmithKline BV

Intervention

Keyword: chemokine antagonist, Crohn's disease, GSK1605786A, induction

Outcome measures

Primary outcome

CDAI decrease from baseline of *100 points at Week 12.

Secondary outcome

CDAI <150 points at week 12, IBDQ score, safety, PK parameters, quality of

life, healthcare related resource utilisation.

Study description

Background summary

GSK1605786A is an orally-administered chemokine antagonist which specifically blocks the migration of gut-specific T cells, which selectively home to the intestine.
Crohn*s disease is a chronic, idiopathic, relapsing inflammatory disorder of the gastrointestinal tract associated with a dysregulated activation of immune cell function. It can affect any portion of the gastrointestinal tract but most commonly affects the terminal small intestine and colon with patients experiencing considerable lifestyle disruption and disability including diarrhoea, abdominal pain, malnutrition and anaemia. Currently there is no curative medical therapy and patients may require treatment for life.
The purpose of this Phase III study is to investigate the efficacy and safety of two doses of GSK1605786A (500 mg once or twice daily) administered orally for 12 weeks as compared with placebo in subjects with moderately-to-severely active Crohn*s disease.
The results of this study are planned to confirm the efficacy and safety of GSK1605786A 500 mg once daily and to establish the benefit-to-risk profile of this dose in the treatment of active Crohn*s disease. In addition, this study

will also assess if a higher dose of 500 mg twice daily that delivers greater plasma exposure can optimise the benefit-to-risk profile.

Study objective

Primary: to assess the efficacy of GSK1605786A compared with placebo as an induction therapy in subjects with moderately-to-severely active Crohn*s disease over 12 weeks. Secondary: Safety, quality of life, healthcare resource utilisation, PK, genetic variants versus efficacy and safety.

Study design

Multicenter randomized double blind phase III parallel group study.
Randomisation (1:1) to treatment with:
1. GSK1605786A 500 mg once daily.
2. GSK1605786A 500 mg twice daily.
3. Placebo.
Plus background therapy (not part of study treatment, on prescription), to be chosen by investigator.
Treatment duration 12 weeks.
Approx 600 patients.
Patients achieving remission during this study are eligible for a double blind randomized placebo controlled follow-up study (CCX114157).

Intervention

Treatment with GSK1605786A or placebo.

Study burden and risks

Risk: Adverse effects of study medication.
Burden: 9 visits in 12 weeks. Duration 0,5-4 h.
Blood tests 9x (approx.50 ml in total), 5 PK samples at different time points (during 1 visit or divided over several visits), pregnancy test (if relevant) 6x, stool investigation 2x, ECG 2x. Questionnaires (EQ 5D, SF-36, IBDQ,WPI-CD) 3x.
During screening daily phone call to answer some questions about the abdominal symtoms. Also during the 8 days preceding visits 4, 6 and 8. Time consumption 5 min/day.
Coloscopy only if not performed during the past 12 months or in case blood and stool tests do not prove moderately to severely active disease. Extra visit necessary.

Contacts

Public
GlaxoSmithKline

Huis ter Heideweg 62
3705 LZ Zeist
NL
Scientific
GlaxoSmithKline

Huis ter Heideweg 62
3705 LZ Zeist
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

* Subjects with Crohn*s disease since > 4 months (small bowel and/or colonic involvement). Confirmed <12 months ago (e.g. endoscopy, capsule endoscopy, MRI or barium X-ray).
* *18 years of age.
* CDAI score of *220 to *450 at Baseline.
* Confirmation of current active Crohn*s disease by either of the following: luminal ulceration visualised by screening endoscopy or elevated CRP (>ULN) plus elevated faecal calprotectin (> 200 *g/g stool) at screening.
* History of inadequate response and/or intolerance leading to discontinuation of at least one of the following treatments for Crohn*s disease: corticosteroids, immunosuppressants.
* Stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn*s disease.

* Safe contraception for women of childbearing potential.

Exclusion criteria

* Breastfeeding, pregnancy.
* Known coeliac disease, those who follow a gluten-free diet to manage symptoms of suspected coeliac disease and subjects with a positive screening test for celiac disease.
* Known or suspected small bowel stricture
* Enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period.
* Bowel surgery, other than appendectomy, within 12 weeks prior to screen.
* Use of prohibited medications (see protocol for details).
* Usual exclusion criteria for biologicals.
* QTc *450 msec (480 msec for those with Bundle Branch Block)

Study design

Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	01-01-2011
Enrollment:	30
Type:	Anticipated

Medical products/devices used

Product type:	Medicine

Brand name:	GSK1605786A
Generic name:	GSK1605786A

Ethics review

Approved WMO Date:	09-11-2010
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	19-04-2011
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	28-04-2011
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	15-06-2011
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	05-09-2011
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	08-09-2011
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	12-04-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	24-04-2012
Application type:	Amendment

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
Other	clinicaltrials.gov, registratienummer n.n.b.
EudraCT	EUCTR2010-022382-10-NL
CCMO	NL34539.018.10